CHM and choroideremia: Encouraging results from a recent phase 2 clinical trial showed that high-dose subfoveal gene therapy using an adeno-associated virus (AAV) expressing REP-1 (AAV2-REP-1) has the potential to maintain, and in some cases improve, the best-corrected visual acuity (BCVA) of patients with choroideremia [19].